Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine
It remains unclear whether unipolar psychotic depression should be treated with an antidepressant and an antipsychotic or with an antidepressant alone. Method:
In a multi-center RCT, 122 patients (18–65 years) with DSM-IV-TR psychotic major depression and HAM-D-17 ≥ 18 were randomized to 7 weeks imipramine (plasma-levels 200–300 μg/l), venlafaxine (375 mg/day) or venlafaxine–quetiapine (375 mg/day, 600 mg/day). Primary outcome was response on HAM-D-17. Secondary outcomes were response on CGI and remission (HAM-D-17). Results:
Venlafaxine–quetiapine was more effective than venlafaxine with no significant differences between venlafaxine–quetiapine and imipramine, or between imipramine and venlafaxine. Secondary outcomes followed the same pattern. Conclusion:
That unipolar psychotic depression should be treated with a combination of an antidepressant and an antipsychotic and not with an antidepressant alone, can be considered evidence based with regard to venlafaxine–quetiapine vs. venlafaxine monotherapy. Whether this is also the case for imipramine monotherapy is likely, but cannot be concluded from the data.
Document Type: Research Article
Affiliations: 1: Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, the Netherlands 2: Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands 3: Department of Psychiatry, Radboud University Nijmegen Medical Center, the Netherlands 4: Department of Psychiatry, Isala Klinieken, Location Sophia, Zwolle, the Netherlands 5: Department of Psychiatry, St. Antonius-Mesos Hospital, Utrecht, the Netherlands 6: Department of Psychiatry, Waterland Hospital, Purmerend, the Netherlands 7: Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
Publication date: 2010-03-01